Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.

Hoogland, Agnes Marije; Dahlman, Anna K; Vissers, Kees J; Wolters, Tineke; Schröder, Fritz; Roobol, Monique; Bjartell, Anders; van Leenders, Geert J L H

Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.

Mark

Hoogland, Agnes Marije ; Dahlman, Anna K ^LU ; Vissers, Kees J ; Wolters, Tineke ; Schröder, Fritz ; Roobol, Monique ; Bjartell, Anders ^LU and van Leenders, Geert J L H (2011) In BJU International 108(8). p.1356-1362

Abstract: OBJECTIVES: • To investigate whether cysteine-rich secretory protein 3 (CRISP-3) and/or β-microseminoprotein (β-MSP) expression in diagnostic prostate needle biopsies have predictive value for prostate cancer (PC) on radical prostatecomy (RP). • To evaluate their potential clinical implementation in a preoperative setting. PATIENTS AND METHODS: • In total, 174 participants from the European Randomized Study of Screening for Prostate Cancer, Rotterdam section, treated by RP for PC were included in the present study. • CRISP-3 and β-MSP immunohistochemistry was performed on corresponding diagnostic needle biopsies. • Outcome was correlated with clinicopathological parameters (prostate-specific-antigen, PSA; number of positive biopsies;... (More); OBJECTIVES: • To investigate whether cysteine-rich secretory protein 3 (CRISP-3) and/or β-microseminoprotein (β-MSP) expression in diagnostic prostate needle biopsies have predictive value for prostate cancer (PC) on radical prostatecomy (RP). • To evaluate their potential clinical implementation in a preoperative setting. PATIENTS AND METHODS: • In total, 174 participants from the European Randomized Study of Screening for Prostate Cancer, Rotterdam section, treated by RP for PC were included in the present study. • CRISP-3 and β-MSP immunohistochemistry was performed on corresponding diagnostic needle biopsies. • Outcome was correlated with clinicopathological parameters (prostate-specific-antigen, PSA; number of positive biopsies; Gleason score, GS; pT-stage; surgical margins at RP) and significant PC at RP (pT3/4, or GS > 6, or tumour volume ≥0.5 mL) in the total cohort (n= 174) and in a subgroup with low-risk features at biopsy (PSA ≤ 10 ng/ml, cT ≤ 2, PSA density <0.20 ng/mL/g, GS < 7 and ≤2 positive biopsy cores; n= 87). RESULTS: • β-MSP and CRISP-3 expression in PC tissue was heterogeneous, with variable staining intensities occurring in the same tissue specimen. • High expression of β-MSP significantly correlated with GS < 7 at RP; it was not a predictor for significant PC at RP neither in the total group (n= 174; odds ratio, OR, 0.319; 95% confidence interval, CI, 0.060-1.695; P= 0.180), nor in the low-risk group (n= 87; OR, 0.227; 95% CI, 0.040-1.274; P= 0.092). • CRISP-3 expression was not related to clinicopathological parameters, and did not predict significant PC at RP in the total group (n= 174; OR, 1.056; 95% CI, 0.438-2.545; P= 0.904) or the low-risk group (n= 87; OR, 1.856; 95% CI, 0.626-5.506; P= 0.265). CONCLUSIONS: • High β-MSP expression correlated with low GS in subsequent RP specimens, supporting the view that β-MSP exerts a tumour-suppressive effect. • No significant prognostic value of β-MSP or CRISP-3 in prostate needle biopsies for significant PC at RP was found. • β-MSP or CRISP-3 do not have additional value in the therapeutic stratification of patients with PC. (Less)

Please use this url to cite or link to this publication: https://lup.lub.lu.se/record/1883898

author

Hoogland, Agnes Marije ; Dahlman, Anna K ^LU ; Vissers, Kees J ; Wolters, Tineke ; Schröder, Fritz ; Roobol, Monique ; Bjartell, Anders ^LU and van Leenders, Geert J L H

organization

publishing date

2011

type

Contribution to journal

publication status

published

subject

Urology and Nephrology

keywords

biomarker, prostate cancer, CRISP-3, beta-MSP, prognosis

in

BJU International

volume

108

issue

8

pages

1356 - 1362

publisher

Wiley-Blackwell

external identifiers

wos:000295397000025
pmid:21410630
scopus:80053432526
pmid:21410630

ISSN

1464-4096

DOI

10.1111/j.1464-410X.2010.10059.x

language

English

LU publication?

yes

id

aa36b02f-3780-42be-8c35-92bae993c306 (old id 1883898)

alternative location

http://www.ncbi.nlm.nih.gov/pubmed/21410630?dopt=Abstract

date added to LUP

2016-04-01 11:01:30

date last changed

2022-01-26 04:48:18

@article{aa36b02f-3780-42be-8c35-92bae993c306,
  abstract     = {{OBJECTIVES: • To investigate whether cysteine-rich secretory protein 3 (CRISP-3) and/or β-microseminoprotein (β-MSP) expression in diagnostic prostate needle biopsies have predictive value for prostate cancer (PC) on radical prostatecomy (RP). • To evaluate their potential clinical implementation in a preoperative setting. PATIENTS AND METHODS: • In total, 174 participants from the European Randomized Study of Screening for Prostate Cancer, Rotterdam section, treated by RP for PC were included in the present study. • CRISP-3 and β-MSP immunohistochemistry was performed on corresponding diagnostic needle biopsies. • Outcome was correlated with clinicopathological parameters (prostate-specific-antigen, PSA; number of positive biopsies; Gleason score, GS; pT-stage; surgical margins at RP) and significant PC at RP (pT3/4, or GS &gt; 6, or tumour volume ≥0.5 mL) in the total cohort (n= 174) and in a subgroup with low-risk features at biopsy (PSA ≤ 10 ng/ml, cT ≤ 2, PSA density &lt;0.20 ng/mL/g, GS &lt; 7 and ≤2 positive biopsy cores; n= 87). RESULTS: • β-MSP and CRISP-3 expression in PC tissue was heterogeneous, with variable staining intensities occurring in the same tissue specimen. • High expression of β-MSP significantly correlated with GS &lt; 7 at RP; it was not a predictor for significant PC at RP neither in the total group (n= 174; odds ratio, OR, 0.319; 95% confidence interval, CI, 0.060-1.695; P= 0.180), nor in the low-risk group (n= 87; OR, 0.227; 95% CI, 0.040-1.274; P= 0.092). • CRISP-3 expression was not related to clinicopathological parameters, and did not predict significant PC at RP in the total group (n= 174; OR, 1.056; 95% CI, 0.438-2.545; P= 0.904) or the low-risk group (n= 87; OR, 1.856; 95% CI, 0.626-5.506; P= 0.265). CONCLUSIONS: • High β-MSP expression correlated with low GS in subsequent RP specimens, supporting the view that β-MSP exerts a tumour-suppressive effect. • No significant prognostic value of β-MSP or CRISP-3 in prostate needle biopsies for significant PC at RP was found. • β-MSP or CRISP-3 do not have additional value in the therapeutic stratification of patients with PC.}},
  author       = {{Hoogland, Agnes Marije and Dahlman, Anna K and Vissers, Kees J and Wolters, Tineke and Schröder, Fritz and Roobol, Monique and Bjartell, Anders and van Leenders, Geert J L H}},
  issn         = {{1464-4096}},
  keywords     = {{biomarker; prostate cancer; CRISP-3; beta-MSP; prognosis}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1356--1362}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{BJU International}},
  title        = {{Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.}},
  url          = {{http://dx.doi.org/10.1111/j.1464-410X.2010.10059.x}},
  doi          = {{10.1111/j.1464-410X.2010.10059.x}},
  volume       = {{108}},
  year         = {{2011}},
}

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.